The angiotensin-converting enzyme (ACE) blood test measures the activity of ACE in serum. Clinicians sometimes use it as a supporting marker when sarcoidosis is being considered because cells within sarcoid granulomas can release ACE. An elevated result can fit active or extensive granulomatous inflammation, but it cannot confirm sarcoidosis, locate the affected organ, or distinguish sarcoidosis from every infection and inflammatory disease. Many people with biopsy-proven sarcoidosis have a normal ACE level, while some people without sarcoidosis have a high one. Interpretation is further complicated by age, inherited ACE variation, laboratory method, corticosteroid treatment, and ACE inhibitor medicines such as lisinopril. The test is therefore most useful as one piece of a larger assessment that may include chest imaging, pulmonary function tests, calcium studies, eye and heart evaluation, exclusion of tuberculosis or fungal infection, and biopsy of an accessible abnormal site. A result should answer a focused clinical question rather than serve as a general screen for unexplained symptoms.
- A high ACE level can support sarcoidosis but is not diagnostic, because sensitivity and specificity are too limited for the test to stand alone.
- A normal ACE result does not rule out sarcoidosis, including lung, eye, heart, skin, or neurologic disease.
- ACE inhibitor medicines can markedly lower the measured level, making medication review essential before interpretation.
- Reference ranges vary by laboratory and age, and children and adolescents may have higher normal activity than adults.
- Imaging, organ testing, exclusion of infection, and sometimes biopsy carry more diagnostic weight than the ACE number.
Table of Contents
- What the ACE Blood Test Measures
- Reference Ranges and Factors That Change ACE
- What a High ACE Level Can Mean
- What a Normal or Low ACE Level Means
- How ACE Fits Into a Sarcoidosis Diagnosis
- Using ACE to Monitor Disease or Treatment
- Preparation, Follow-Up, and Urgent Symptoms
What the ACE Blood Test Measures
ACE is an enzyme involved in the renin-angiotensin system, which helps regulate blood pressure and fluid balance. It converts angiotensin I into angiotensin II and also breaks down bradykinin. ACE is found on the surface of endothelial cells, especially in the lungs, and in several other tissues.
In sarcoidosis, activated macrophages and epithelioid cells collect into granulomas—organized clusters of immune cells. These granulomas may produce additional ACE, allowing serum activity to rise. The biological link explains why the test is associated with sarcoidosis, but it does not make ACE specific to the disease. Granulomas have many causes, and ACE production varies greatly between patients.
The test usually measures enzyme activity rather than the concentration of ACE protein. Laboratories may report units per liter or another method-specific unit. The assay is different from blood pressure testing and does not measure angiotensin II directly. It also does not show whether an ACE inhibitor medicine is controlling blood pressure.
An ACE test may be ordered when chest imaging shows bilateral hilar lymph node enlargement, lung nodules, or another pattern that could represent sarcoidosis; when unexplained uveitis, skin lesions, lymph node enlargement, or granulomatous biopsy findings need context; or when a clinician is following a patient whose ACE level was clearly elevated at baseline. It is not a reliable stand-alone test for vague fatigue, cough, or generalized inflammation.
Sarcoidosis can affect nearly any organ, so the blood result must be linked to a specific clinical evaluation. A soluble IL-2 receptor test is another immune-activation marker sometimes considered, but no blood biomarker replaces imaging and organ assessment.
Reference Ranges and Factors That Change ACE
There is no universal ACE reference interval. Results depend on the assay, specimen handling, calibration, age distribution used to establish the range, and local laboratory standards. The only correct “normal range” is the one printed on the patient’s report.
Age is especially important. Children and teenagers can have higher ACE activity than adults because of growth and bone development. Applying an adult cutoff to a younger patient can create a false impression of disease. Pediatric interpretation should use an age-appropriate range from the performing laboratory.
Genetics also affects baseline activity. A common insertion/deletion variation in the ACE gene influences circulating ACE levels. People with one genotype may naturally run higher or lower than people with another genotype even when neither has active disease. Genotype-adjusted interpretation has been studied, but routine clinical laboratories do not always provide it.
Several clinical factors can alter the result:
| Factor | Likely effect | Why it matters |
|---|---|---|
| ACE inhibitor medicine | Lowers ACE activity, sometimes substantially | May make an elevated disease-related level appear normal or low |
| Systemic corticosteroids | May lower ACE as granulomatous inflammation responds | A post-treatment result may not reflect untreated disease |
| Age | Younger people may have higher normal levels | Adult ranges can misclassify pediatric results |
| ACE genotype | Shifts baseline upward or downward | Reduces the accuracy of one fixed cutoff |
| Laboratory method | Changes numeric range | Results from different laboratories may not be directly comparable |
Patients should not stop an ACE inhibitor merely to obtain a higher test result. These medicines may be essential for blood pressure, heart failure, or kidney protection. The clinician can decide whether the test has value while the medicine is continued or whether another diagnostic approach is better.
Angiotensin receptor blockers, such as losartan, do not inhibit ACE in the same direct way, although the complete medication list still matters. The timing of corticosteroid therapy should also be recorded because an ACE level drawn after treatment begins can be lower than the pretreatment level.
What a High ACE Level Can Mean
A high ACE level means serum enzyme activity exceeded the laboratory’s reference interval. It does not specify a diagnosis. Sarcoidosis is a common reason clinicians order the test, but the positive predictive value depends heavily on the patient’s imaging and symptoms.
A high result carries more meaning when several features align, such as:
- bilateral hilar or mediastinal lymphadenopathy on chest imaging;
- a compatible perilymphatic lung-nodule pattern;
- noncaseating granulomas on biopsy;
- uveitis, lupus pernio, erythema nodosum, or other characteristic manifestations;
- exclusion of mycobacterial, fungal, occupational, medication-related, and malignant causes;
- elevated calcium or other organ findings consistent with sarcoidosis.
Even in this setting, ACE supports rather than establishes the diagnosis. Granulomas described as “noncaseating” are not unique to sarcoidosis. Tuberculosis, nontuberculous mycobacteria, histoplasmosis and other fungal infections, beryllium exposure, immune deficiencies, drug reactions, inflammatory bowel disease, and cancer-associated reactions may produce granulomatous tissue findings.
High ACE has also been reported in other conditions, including Gaucher disease, leprosy, some granulomatous infections, hyperthyroidism, diabetes, liver disease, and certain hematologic or inflammatory disorders. The strength and consistency of these associations vary. A clinician should not infer one of these diseases from ACE alone; the result only broadens or redirects the differential diagnosis when the clinical picture supports it.
The degree of elevation does not reliably grade organ danger. A person with mild pulmonary disease may have a high value, while someone with cardiac or neurologic sarcoidosis may have a normal one. ACE cannot determine whether the heart, brain, eyes, kidneys, or lungs are involved.
A high result should therefore lead to targeted questions: Why was the test ordered? Does imaging support granulomatous disease? Is there a safer site to biopsy? Have infections been excluded? Are there symptoms of cardiac, neurologic, eye, or calcium-related complications that require immediate evaluation?
What a Normal or Low ACE Level Means
A normal ACE level does not exclude sarcoidosis. Reported sensitivity varies widely across studies and patient populations, which means a substantial proportion of people with confirmed disease have values inside the reference interval. The test can be normal in early disease, limited disease, chronic fibrotic disease, disease involving certain organs, or disease already treated with corticosteroids.
A normal result is especially difficult to interpret in a person taking an ACE inhibitor. Lisinopril, enalapril, ramipril, benazepril, captopril, and related medicines reduce the activity being measured. The report may be low or undetectable even when granulomatous inflammation is present.
A low ACE value rarely identifies one specific illness. It may reflect medication effect, laboratory variation, an individual’s genetic baseline, or reduced activity reported with some chronic conditions. Low results are generally less useful diagnostically than elevated results.
When clinical suspicion remains high, the next step is not simply to repeat ACE until it becomes abnormal. Evaluation should move toward the organ in question. For pulmonary disease, chest CT, pulmonary function tests, bronchoscopy, endobronchial ultrasound-guided lymph node sampling, or another biopsy route may be appropriate. For eye disease, a full ophthalmologic examination is more informative. For possible cardiac sarcoidosis, ECG, rhythm monitoring, echocardiography, cardiac MRI, or PET may be needed.
A normal ACE can provide modest reassurance only when the overall probability of sarcoidosis was already low. It should not override classic imaging, a compatible biopsy, or serious organ symptoms.
How ACE Fits Into a Sarcoidosis Diagnosis
Sarcoidosis is diagnosed through a combination of compatible clinical or radiologic findings, granulomatous inflammation when tissue is needed, and exclusion of alternative causes. No single blood test fulfills all three requirements.
The diagnostic pathway usually begins with the organ presentation. Pulmonary sarcoidosis commonly produces hilar and mediastinal lymph node enlargement, perilymphatic nodules, or upper-lung-predominant changes. Skin disease may produce lupus pernio or papules. Eye involvement can cause uveitis. Cardiac disease may present with conduction block, ventricular arrhythmia, fainting, or cardiomyopathy. Neurologic disease can affect cranial nerves, the meninges, brain, spinal cord, or peripheral nerves.
Biopsy is often taken from the safest accessible abnormal site rather than the most dangerous organ. Enlarged chest lymph nodes may be sampled by endobronchial ultrasound. Skin lesions, peripheral lymph nodes, or conjunctival lesions can sometimes provide tissue with less risk than lung, heart, or nervous-system biopsy.
The pathologist looks for nonnecrotizing granulomas, but the clinical team must still exclude mimics. Microbiologic stains, cultures, exposure history, immune status, imaging distribution, and medication review help make that distinction.
Some highly characteristic clinical syndromes may be diagnosed without biopsy after specialist evaluation. Examples include Löfgren syndrome, which classically combines bilateral hilar lymphadenopathy, ankle periarthritis, and erythema nodosum, and certain other well-defined presentations. ACE may be supportive but is not what makes these syndromes characteristic.
A practical sarcoidosis evaluation may include:
- chest radiography or CT;
- pulmonary function testing;
- CBC, liver enzymes, creatinine, calcium, and urine studies;
- ECG and symptom-directed cardiac testing;
- baseline eye examination;
- infection testing guided by geography and exposure;
- biopsy when the diagnosis remains uncertain or organ risk requires confirmation.
General inflammatory markers such as the CRP test or ESR test can show inflammation but are also nonspecific. ACE should be understood in the same supporting role, with additional limitations from medication and genetics.
Other proposed sarcoidosis biomarkers do not eliminate the need for this clinical framework. Soluble interleukin-2 receptor may better reflect activated immune cells in some patients, while chitotriosidase, lysozyme, and selected imaging or organ-specific markers can add information in specialized settings. Each has limitations related to availability, genetics, kidney function, medication, or lack of disease specificity. No biomarker has become a universal standalone test.
Consider two contrasting examples. A patient with bilateral hilar lymph-node enlargement, compatible lung nodules, no infectious explanation, and a high ACE level has a result that supports an already coherent picture; biopsy may still be needed depending on certainty and treatment plans. Another patient with unexplained heart block and a normal ACE level may still need urgent cardiac imaging and specialist evaluation because serum ACE is not sensitive enough to exclude cardiac sarcoidosis. The same laboratory number carries different weight because the clinical stakes and pretest probability are different.
This is why clinicians should avoid ordering broad biomarker panels without a diagnostic question. Tests are most useful when they help decide among plausible causes, identify organ involvement, or establish a reproducible baseline. They are least useful when a mildly abnormal result becomes the only reason to label someone with sarcoidosis.
Using ACE to Monitor Disease or Treatment
Serial ACE measurements are sometimes used when a patient had a clearly elevated value at diagnosis and that value changed consistently with known disease activity. In that narrow setting, the trend may provide supplementary information. It should not be the main reason to start, stop, or intensify treatment.
ACE may fall after corticosteroid therapy or after granulomatous burden decreases. A falling level can be encouraging, but it does not prove that every involved organ has improved. Cardiac rhythm disease, eye inflammation, neurologic injury, or pulmonary fibrosis may persist despite a normal serum value.
Likewise, a rising ACE level does not by itself prove relapse. Biological variation, assay change, medication changes, and genotype-related baseline differences can affect the number. A patient may also remain clinically stable despite an elevated value.
Monitoring should match the organ at risk:
- Lungs: symptoms, oxygen level, pulmonary function tests, and imaging when indicated.
- Heart: ECG, rhythm monitoring, imaging, ventricular function, and symptoms such as fainting or palpitations.
- Eyes: slit-lamp examination and visual symptoms.
- Nervous system: neurologic examination, MRI, cerebrospinal fluid studies, and functional changes.
- Calcium metabolism: serum calcium, kidney function, urine calcium in selected patients, and vitamin D metabolite assessment when appropriate.
- Liver or spleen: enzymes, blood counts, imaging, and clinical findings.
Treatment decisions depend on organ threat, symptoms, functional decline, and likelihood of preventing damage. Many people with pulmonary sarcoidosis improve spontaneously and do not need systemic treatment. Others require glucocorticoids or steroid-sparing therapy. ACE is not a treatment threshold.
When serial testing is used, the same laboratory and assay are preferable. A result from a new method should be treated as a new baseline rather than compared numerically without caution.
Preparation, Follow-Up, and Urgent Symptoms
The ACE test requires a venous blood sample. Fasting is usually unnecessary unless other ordered tests require it. The patient should provide a complete medication list, especially ACE inhibitors and corticosteroids, and should mention the date treatment began.
Useful follow-up questions include:
- What is the laboratory’s age-appropriate reference range?
- Am I taking an ACE inhibitor that makes the result uninterpretable?
- What imaging or organ finding caused sarcoidosis to be considered?
- Have tuberculosis, fungal infection, occupational exposure, and medication reactions been addressed?
- Is there an accessible site for biopsy?
- Which organ-specific tests matter more than repeating ACE?
- Was my baseline ACE elevated enough and consistent enough to make future trends useful?
Urgent evaluation is warranted for fainting, sustained palpitations, chest pain, new severe shortness of breath, sudden weakness, facial paralysis with other neurologic symptoms, severe headache with confusion, seizure, rapid vision change, severe eye pain, or symptoms of marked hypercalcemia such as vomiting, dehydration, confusion, and profound weakness. These can signal cardiac, neurologic, ocular, or metabolic sarcoidosis complications and should not wait for an ACE result.
The ACE blood test is best viewed as a context-dependent clue. A high level can reinforce a coherent sarcoidosis evaluation; a normal level cannot close the case. The diagnosis and follow-up should remain anchored to organs, imaging, exclusion of mimics, and tissue evidence when needed.
References
- Biomarkers in Sarcoidosis: From Traditional Markers to Precision Medicine 2025 (Review)
- Put Down the ACE: Low Clinical Utility for Angiotensin-Converting Enzyme Levels in Sarcoidosis: A Single-Center Retrospective Cohort Study 2024 (Study)
- Sarcoidosis: A Review of the Guidelines and What’s To Come 2024 (Review)
- Re-evaluating serum angiotensin-converting enzyme in sarcoidosis 2023 (Review)
- Establishing a Diagnosis of Pulmonary Sarcoidosis 2023 (Review)
- Performance of Serum Angiotensin-Converting Enzyme in Diagnosing Sarcoidosis and Predicting the Active Status of Sarcoidosis: A Meta-Analysis 2022 (Meta-Analysis)
Disclaimer
This article provides general education and cannot diagnose sarcoidosis or another granulomatous disease. ACE results must be interpreted with age, medications, imaging, organ testing, infection assessment, and sometimes biopsy. Seek urgent care for fainting, dangerous heart-rhythm symptoms, sudden neurologic changes, severe breathing difficulty, or rapid vision loss.
